News

Ginger Hultin, MS, RDN, explained the benefits of an anti-inflammatory nutrition plan for patients living with rheumatic and autoimmune conditions, as well as what rheumatologists need to know.

An analysis of the DELIVER and DAPA-HF trials provides an overview of the impact of gout on heart failure outcomes and effects of dapagliflozin in this patient population.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.

Compared with treatments like allopurinol, nanoparticles can improve the biocompatibility and bioavailability while reducing toxicity and side effects in patients with gout.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

Data from the phase 2 CLUE trial provide insight into the safety and efficacy of tigulixostat as a serum urate-lowering therapy in patients with gout with hyperuricemia.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.

Investigators noted that presenting tophi in perioperative patients was found to be an independent risk factor for gout recurrence within the first year postoperative.

While high-sensitive Troponin T (hsTnT) is primarily used as a marker of heart disease, data suggests its potential as a useful marker of inflammation in the joints.

While the benzbromarone group had a slightly higher rate compared to the control group, this difference did not reach statistical significance.

Patients receiving guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months.

Electronic patient-reported outcome (ePRO) questionnaires may allow rheumatologists to better understand the patient's experience and monitor improvements over time.

The study utilized a nationwide cohort of patients with hemodialysis and peritoneal dialysis to evaluate gout prevalence, practice patterns, and clinical associations.

Investigators hypothesized that patients with fibromyalgia who avoid activities because of pain would be more likely to perceive more intense pain levels after walking due to catastrophizing.

An analysis of survey data from more than 2000 patients in Western Sweden is providing insight into how the impact of inflammatory joint disease on health-related quality of life differs among those with gout, RA, PsA, and ankylosing spondylitis.

The systematic review compared mHealth interventions with conventional treatment or nonintervention to determine the pain management effects of mobile-based self-management strategies.

Results may help minimize the risk of developing hyperuricemia, gout, and related adverse events in patients receiving antihypertensive drugs.

As an industry and a society, we must take gout more seriously. That effort begins with the physicians who diagnose and treat it.

Musculoskeletal ultrasound evaluated tophus size and double contour sign in lower extremity joints of patients with gout before and after initiating uric acid lowering therapy.

The DECT scoring system obtained excellent diagnostic performance for differentiating early-stage gout from middle-stage gout, with sensitivity, positive and negative predictive values, and specificity all achieving an accuracy of > 85%.

The majority of included studies observed improvements in pain, fatigue, patient global, sleep disturbance, multidimensional function, and tender points.

An international review of data show certain antidepressants may benefit conditions like fibromyalgia, but many trials are actually inconclusive.

Anakinra effectively treated 94% of the gout flares included in the study sample and was a viable long-term treatment option.

Adult patients with psoriatic arthritis starting a second-line biological after discontinuing a TNF were enrolled in the nationwide cohort study.

“Reversing and preventing adverse lifestyle factors could potentially reduce the incidence and burden of rheumatoid arthritis, as well as alleviate its comorbidities,” investigators hypothesized.

Investigators measured pain intensity, the primary outcome, as well as physical function, isometric strength, quality of life, and fibromyalgia impact at baseline and the 6-month mark.

Katinka Albrecht, MD, and Johanna Callhoff, MSc, discuss the results of their recent study evaluating patients with rheumatoid arthritis and concomitant interstitial lung disease.

An analysis of data from 4 phase 2/3 studies provides insight into the effects of guselkumab in psoriatic arthritis based on whether or not a person had prior exposure to TNF inhibitor therapy.

"All forms of arthritis can make life difficult for people because of the pain, swelling, or stiffness in a joint or joints, and because of difficulties in getting about," investigators explained.

In a recent study, DLE patients responded well to topical niacinamide 2% and 4% as adjuvant therapy, with strong results and few side effects.